Page last updated: 2024-12-05

trientine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5565
CHEMBL ID609
CHEBI ID39501
SCHEMBL ID15439
SCHEMBL ID6423840
MeSH IDM0021952

Synonyms (112)

Synonym
BIDD:GT0014
BIDD:ER0303
n,n'-bis(2-aminoethyl)ethane-1,2-diamine
1,2-ethanediamine, n,n'-bis(2-aminoethyl)-
NCGC00091695-01
ethylenediamine, n,n'-bis(2-aminoethyl)-
hsdb 1002
trientina [inn-spanish]
araldite hy 951
ai3-24384
triethylene tetramine
nsc 443
1,4,7,10-tetraazadecane
1,8-diamino-3,6-diazaoctane
n,n-bis(2-aminoethyl)-1,2-diaminoethane
brn 0605448
araldite hardener hy 951
trientinum [inn-latin]
hy 951
un2259
ccris 6279
einecs 203-950-6
3,6-diazaoctane-1,8-diamine
nsc-443
nsc443
ethylenediamine,n'-bis(2-aminoethyl)-
trien
C07166
n,n'-bis(2-aminoethyl)ethylenediamine
deh 24
tecza
wln: z2m2m2z
1,7,10-tetraazadecane
teta
1,6-diazaoctane
triethylenetetramine
trientine
112-24-3
3,8-diamine
2,2,2-tetramine
CHEBI:39501 ,
n,n'-bis(2-aminoethyl)-1,2-ethanediamine
triethylenetetramine, technical grade, 60%
n1,n1'-(ethane-1,2-diyl)diethane-1,2-diamine
triethylenetetramine, >=97.0% (t)
CHEMBL609 ,
trethylenetetramine
triethylene tetraamine
BMSE000773
T0429
n,n'-di(2-aminoethyl)ethylenediamine
n'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine
NCGC00091695-04
NCGC00091695-03
NCGC00258619-01
tox21_201066
bdbm50323751
n,n''-bis(2-aminoethyl)-1,2-ethanediamine
n,n''-bis-(2-amino-ethyl)-ethane-1,2-diamine
AKOS006223906
cas-112-24-3
dtxsid9023702 ,
tox21_111162
dtxcid503702
trientine [inn]
trientinum
triethylenetetramine [un2259] [corrosive]
sj76y07h5f ,
4-04-00-01242 (beilstein handbook reference)
1,2-ethanediamine, n1,n2-bis(2-aminoethyl)-
tomography, x-ray computed trientine
trientina
unii-sj76y07h5f
BP-30180
STL477736
trientine [mi]
trientine [who-dd]
trientine [vandf]
triethylenetetramine [hsdb]
SCHEMBL15439
tox21_111162_1
triethylenetetraamine
SCHEMBL6423840
ethanediamine, n,n'-bis(2-aminoethyl)-
n,n'-bis(2-aminoethyl)-1,2-diaminoethane
texlin 300 (salt/mix)
3,6-diazaoctanethylenediamin
trientene
W-109064
AB00573244_07
n1,n2-bis(2-aminoethyl)-1,2-ethanediamine
eph 925
mfcd00008169
DB06824
EN300-651158
rt 1ax
rutapox ve 2896
teta (crosslinking agent)
ve 2896
J-018026
SBI-0206814.P001
(2-aminoethyl)({2-[(2-aminoethyl)amino]ethyl})amine
Q418386
105821-86-1
STR03562
triene
trientinum (inn-latin)
trientina (inn-spanish)
n,n'-bis(2-aminoethyl)ethanediamine
n,n'-bis(aminoethyl)ethylenediamine
a16ax12
n,n'-bis-(2-aminoethyl)ethylenediamine

Research Excerpts

Overview

Trientine is a highly selective copper II chelator. Trientine proved to be an effective alternative copper chelating agent in the treatment of Wilson's disease.

ExcerptReferenceRelevance
"Trientine is a highly selective copper II chelator."( Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Akhtar, M; Ashkir, Z; Baroja, O; Bedson, E; Clayton, D; Cooper, RM; Dodd, S; Duran, B; Farrant, J; Garratt, C; Harrington, C; Mahmod, M; Miller, CA; Naish, JH; Neubauer, S; Prasad, SK; Raman, B; Reid, A; Schmitt, M; Singh, A; Spowart, C; Valkovič, L; Vaughan, C, 2023
)
1.89
"Trientine proved to be an effective alternative copper chelating agent in the treatment of Wilson's disease in patients with penicillamine-induced neutropenia, thrombocytopenia, SLE, and nephrosis."( Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
Dubois, RS; Hambidge, KM; Rodgerson, DO, 1990
)
1.23

Effects

ExcerptReferenceRelevance
"Trientine has been considered an option for initial treatment and maintentance therapy of WD due to its safety profile."( Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature.
Boga, S; Jain, D; Schilsky, ML, 2015
)
2.58

Actions

ExcerptReferenceRelevance
"Trientine failed to increase copper excretion in the urine when compared to the unmedicated and non-copper-loaded control groups."( The cupruretic effect of two chelators following copper loading in sheep.
Botha, CJ; Dauth, J; Dreyer, MJ; Naude, TW; Swan, GE; Williams, MC, 1993
)
1.01

Treatment

Trientine treatment decreased LVM(bsa) by 5.0 +/- 7.2 g/m(2) (mean +/- SD) at month 6. Treatment over the first 4 weeks gave 72% protection; intervention therapy over the final 4 weeks prevented deterioration and corrected the initial deficit by 68%. Trientine also caused elevated Cu excretion in humans with type 2 diabetes.

ExcerptReferenceRelevance
"Trientine treatment was safe and tolerated. "( Copper chelation in patients with hypertrophic cardiomyopathy.
Clark, D; Cooper, G; Farrant, JP; Miller, C; Polturi, R; Ray, S; Reid, A; Schmitt, M, 2022
)
2.16
"Trientine treatment decreased LVM(bsa) by 5.0 +/- 7.2 g/m(2) (mean +/- SD) at month 6 (when 14 trientine-treated and 14 placebo-treated participants were analysed; p = 0.0056 compared with placebo) and by 10.6 +/- 7.6 g/m(2) at month 12 (when nine trientine-treated and 13 placebo-treated participants were analysed; p = 0.0088), whereas LVM(bsa) was unchanged by placebo treatment."( A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Baker, JR; Brunton, DH; Cooper, GJ; Cowan, BR; Dissanayake, AM; Doughty, RN; Frampton, CM; Gamble, GD; Occleshaw, CJ; Phillips, AR; Poppitt, SD; Young, AA, 2009
)
1.07
"Trientine treatment significantly improved cardiac function in diabetic rats with substantive LV impairment. "( Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
Choong, SY; Cooper, GJ; Cowan, BR; Gamble, GD; Li, M; Lu, J; Phillips, AR; Pickup, S; Pontré, B; Xu, H; Young, AA, 2013
)
1.83
"Trientine treatment over the first 4 weeks gave 72% protection; intervention therapy over the final 4 weeks prevented deterioration and corrected the initial deficit by 68%."( Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats.
Cameron, NE; Cotter, MA; Inkster, ME, 2002
)
1.43
"Oral trientine treatment also caused elevated Cu excretion in humans with type 2 diabetes, in whom 6 months of treatment caused elevated left ventricular mass to decline significantly toward normal."( Regeneration of the heart in diabetes by selective copper chelation.
Allen, GR; Baker, JR; Borg, TK; Boyd, PD; Brunton, DH; Chan, YK; Choong, SY; Cooper, GJ; Cowan, BR; Crossman, DJ; Dissanayake, AM; Doughty, RN; Gamble, GD; Keogh, GF; Leahy, FE; Leonard, BL; Occleshaw, CJ; Phillips, AR; Pope, AJ; Poppitt, SD; Saafi, 'L; Young, AA, 2004
)
0.78
"Trientine treatment resulted in a marked suppression of neovascularization and increase of apoptosis in the tumor, whereas tumor cell proliferation itself was not altered."( The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
De Lorenzo, MS; Fukui, H; Gomez, DE; Ikenaka, Y; Kishida, H; Kuriyama, S; Nakae, D; Nakatani, T; Noguchi, R; Okuda, H; Tejera, AM; Tsujinoue, H; Yoshii, J; Yoshiji, H, 2001
)
1.33
"Treatment with trientine, a divalent-copper-selective chelator, improves arterial and renal structure/function in diabetes, wherein it also ameliorates left-ventricular (LV) hypertrophy."( Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
Choong, SY; Cooper, GJ; Cowan, BR; Gamble, GD; Li, M; Lu, J; Phillips, AR; Pickup, S; Pontré, B; Xu, H; Young, AA, 2013
)
0.73

Toxicity

Chelating agents are effective therapies for most patients with Wilson disease. D-penicillamine and trientine produce comparable outcomes, although D-Penicillamines had a higher rate of adverse events.

ExcerptReferenceRelevance
"6 times their respective LD50 values in order to compare their relative effectiveness in prevention of death caused by exposure for 15 min to inhalation of nickel carbonyl (1."( Comparisons of antidotal efficacy of sodium diethyldithiocarbamate, D-penicillamine and triethylenetetramine upon acute toxicity of nickel carbonyl in rats.
Baselt, RC; Horak, E; Mitchell, J; Sunderman, FW, 1977
)
0.26
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Chelator-based treatment regimens were analyzed for their effect on neurologic and hepatic symptoms and for adverse events that led to discontinuation of therapy (Kaplan-Meier estimation; data were collected for a mean of 13."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.39
" Adverse events leading to discontinuation of treatment were more frequent among those receiving D-penicillamine than trientine (P = ."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.6
"Chelating agents are effective therapies for most patients with Wilson disease; D-penicillamine and trientine produce comparable outcomes, although D-penicillamine had a higher rate of adverse events."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.61
"BACKGROUND AND OBJECTIVE: There are limited data on the adverse events of D-penicillamine in Wilson's disease (WD) that can result in dose modification or treatment discontinuation."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Adverse events (AEs) related to D-penicillamine treatment, the timing and management of these AEs were analysed."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Overall, most common AEs were hematological [16, 57% (pancytopenia n = 8, bicytopenia n = 5 and hemolytic anemia n = 3)] while renal adverse events (n = 7, 25%) constituted the most common indication for permanent discontinuation."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Temporary cessation of drug with reintroduction at a lower dose is an effective and safe option."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Safety of TETA 4HCl treatment was based on reported adverse events (AEs)."( Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
Bourhis, H; Denk, G; Merle, U; Mohr, I; Morgil, M; Morvan, E; Obadia, MA; Poujois, A; Weiss, KH; Woimant, F, 2023
)
1.22
" This study indicates that the switch from TETA 2HCl to TETA 4HCl is safe and viable."( Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
Bourhis, H; Denk, G; Merle, U; Mohr, I; Morgil, M; Morvan, E; Obadia, MA; Poujois, A; Weiss, KH; Woimant, F, 2023
)
1.22

Pharmacokinetics

ExcerptReferenceRelevance
" There were no significant differences in material balance or pharmacokinetic parameters among animals receiving DETA."( Pharmacokinetics and material balance studies of diethylenetriamine trihydrochloride in the Fischer 344 rat following oral, endotracheal or intravenous dosing.
Leung, HW; Tyler, TR,
)
0.13
" They present, for the first time, the complete 24-hour pharmacokinetic profiles of TETA, MAT, and DAT in humans."( Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.
Cooper, GJ; Diamond, LE; Garcia, WD; Lu, J; Othman, AA; Poppitt, SD; Roesch, BG; Ruggiero, K; Sunderland, T; Willett, MS, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of TE was below 10% and the plasma levels of TE in non-fasted rats were significantly lower than that observed in fasted rats."( [Intestinal absorption and urinary excretion of triethylenetetramine for Wilson's disease in rat].
Iseki, K; Kobayashi, M; Miyazaki, K; Saitoh, H; Sugawara, M, 1990
)
0.28
" The bioavailability of TETA in the rat was also examined and the ratio of intestinal absorption was extremely low."( Determination of triethylenetetramine in plasma of patients by high-performance liquid chromatography.
Arashima, S; Arita, T; Kishino, S; Kobayashi, M; Matsumoto, S; Miyazaki, K, 1990
)
0.28
"Food-drug interactions may reduce the bioavailability of drugs taken after meals (negative food effect)."( Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.
Kamaguchi, R; Kataoka, M; Kokubo, H; Kozaki, T; Masaoka, Y; Sakuma, S; Tanno, FK; Yamashita, S, 2007
)
0.34
" TETA is poorly absorbed with a bioavailability of 8 to 30%."( Triethylenetetramine pharmacology and its clinical applications.
Lu, J, 2010
)
0.36
" The bioavailability of PACAs can be improved by the addition of differing lengths of alkyl side chains that alter amphipathic properties."( Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation.
Bowman, BM; Miller, SC; Wang, X, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" When a dosage level of 8 mg of gentamicin was exceeded in the combined treatment regimen, all of the infected mice died, and a high concentration of endotoxin could be detected in the mouse sera by the limulus assay."( The effect of triethylenetetramine dihydrochloride on the in vivo susceptibility of Pseudomonas aeruginosa to gentamicin.
Light, B; Riggs, HG, 1979
)
0.26
" After 24 h treatment with amine, the MAO activity of cultured skin fibroblasts was elevated in a dose-response manner."( Increased activity of monoamine oxidase by epoxy resin hardeners.
Yano, E, 1987
)
0.27
" Analytical chemical procedures to determine the purity of the drug as well as the proper concentration and stability of the drug in dosed water were prerequisites for the toxicological tests."( Determination of triethylenetetramine dihydrochloride in aqueous solution by reversed-phase ion-pairing high performance liquid chromatography and conductivity detection.
Hansen, EB; Rushing, LG; Thompson, HC,
)
0.13
"3HCl) were studied with regard to route of administration and dosage effects."( Pharmacokinetics and material balance studies of diethylenetriamine trihydrochloride in the Fischer 344 rat following oral, endotracheal or intravenous dosing.
Leung, HW; Tyler, TR,
)
0.13
" Trientine hydrochloride was orally administered in a single daily dose of 250 mg to 12 patients before a meal (at fasting, group 1) or at a total daily dosage of 750 mg, divided into 3 doses, to 12 patients (group 2)."( Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy.
Ebara, M; Fukuda, H; Kondo, F; Okabe, S; Saisho, H; Sugiura, N; Yoshikawa, M; Yukawa, M, 2004
)
1.43
" Twenty-four-hour urine collections were performed before and after dosing participants."( Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Chan, YK; Cooper, GJ; Gamble, GD; Lu, J; Othman, AA; Poppitt, SD, 2007
)
0.34
" For Co studies, animals received a single dose of Cuprimine or Syprine, while for Po studies animals were repeatedly dosed at 24-h intervals for a total of 5 doses."( Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po.
Creim, JA; Curry, TL; Levinson, B; Levitskaia, TG; Luders, T; Morris, JE; Thrall, KD; Woodstock, AD, 2010
)
0.36
" Standardized dosage strategies that address changes in copper pools might improve adherence and reduce side effects."( Clinical considerations for an effective medical therapy in Wilson's disease.
Stremmel, W; Weiss, KH, 2014
)
0.4
" To examine the impact of different weight-based dosages, 2 dosage subgroups were analyzed."( Optimized Trientine-dihydrochloride Therapy in Pediatric Patients With Wilson Disease: Is Weight-based Dosing Justified?
Ferenci, P; Fichtner, A; Hoffmann, GF; Mayr, T; Mehrabi, A; Mohr, I; Pfeiffenberger, J; Teufel-Schäfer, U; Weiler, M; Weiss, KH, 2021
)
1.02
"Investigations about weight-based dosage showed no significant difference of any laboratory parameter between the 2 cohorts."( Optimized Trientine-dihydrochloride Therapy in Pediatric Patients With Wilson Disease: Is Weight-based Dosing Justified?
Ferenci, P; Fichtner, A; Hoffmann, GF; Mayr, T; Mehrabi, A; Mohr, I; Pfeiffenberger, J; Teufel-Schäfer, U; Weiler, M; Weiss, KH, 2021
)
1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
copper chelatorA chelator that is any compound containing a ligand (typically organic) which is able to form a bond to a central copper atom at two or more points.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tetramineAny polyamine that contains four amino groups.
polyazaalkaneAny azaalkane in which two or more carbons in the chain are replaced by nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
RAR-related orphan receptor gammaMus musculus (house mouse)Potency32.50340.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency42.70560.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency75.94250.000221.22318,912.5098AID743042
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency33.49150.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.87610.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency56.45990.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.13290.001530.607315,848.9004AID1224841; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.23330.000229.305416,493.5996AID1259244
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
lamin isoform A-delta10Homo sapiens (human)Potency0.50120.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.23330.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.23330.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki57.00000.00021.10439.9000AID496922
Carbonic anhydrase 1Homo sapiens (human)Ki100.00000.00001.372610.0000AID496913
Carbonic anhydrase 2Homo sapiens (human)Ki64.00000.00000.72369.9200AID496914
Carbonic anhydrase 3Homo sapiens (human)Ki48.00000.00022.010210.0000AID496915
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki52.00000.00020.566510.0000AID496923
Carbonic anhydrase 4Homo sapiens (human)Ki35.00000.00021.97209.9200AID496916
Carbonic anhydrase 6Homo sapiens (human)Ki43.00000.00011.47109.9200AID496919
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki38.00000.00001.27259.9000AID496917
Carbonic anhydrase 7Homo sapiens (human)Ki45.00000.00021.37379.9000AID496920
Carbonic anhydrase 9Homo sapiens (human)Ki39.00000.00010.78749.9000AID496921
Carbonic anhydrase 15Mus musculus (house mouse)Ki59.00000.00091.884610.0000AID496925
Carbonic anhydrase 13Mus musculus (house mouse)Ki52.00000.00021.39749.9000AID496923
Carbonic anhydrase 14Homo sapiens (human)Ki12.10000.00021.50999.9000AID496924
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki49.00000.00001.34129.9700AID496918
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
angiogenesisDiamine acetyltransferase 1Homo sapiens (human)
polyamine biosynthetic processDiamine acetyltransferase 1Homo sapiens (human)
putrescine catabolic processDiamine acetyltransferase 1Homo sapiens (human)
spermidine acetylationDiamine acetyltransferase 1Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
polyamine biosynthetic processThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
spermidine acetylationThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
spermidine acetylationThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
spermine acetylationThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
putrescine acetylationThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
nor-spermidine metabolic processThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
diamine N-acetyltransferase activityDiamine acetyltransferase 1Homo sapiens (human)
protein bindingDiamine acetyltransferase 1Homo sapiens (human)
N-acetyltransferase activityDiamine acetyltransferase 1Homo sapiens (human)
identical protein bindingDiamine acetyltransferase 1Homo sapiens (human)
spermidine bindingDiamine acetyltransferase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
diamine N-acetyltransferase activityThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
diamine N-acetyltransferase activityThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
protein bindingThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
N-acetyltransferase activityThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
identical protein bindingThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolDiamine acetyltransferase 1Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytoplasmThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
extracellular exosomeThialysine N-epsilon-acetyltransferaseHomo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID88678Inhibitory activity against HeLa cell line using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay.2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Triethylene tetraamine: a novel telomerase inhibitor.
AID496923Inhibition of mouse carbonic anhydrase 13 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1476430Antimigratory activity against human L3.6p1 cells at 1 uM after 24 hrs in presence of amine oxidase inhibitor aminoguanidine by scratch assay relative to control2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Synthesis and Bioevaluation of Macrocycle-Polyamine Conjugates as Cell Migration Inhibitors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496914Inhibition of human carbonic anhydrase 2 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210047Drug metabolism in human HepG2 cells assessed as SSAT2-mediated (N1-acetyl)-triethylenetetramine formation at 1 mM for 24 hrs pretreated with 50 uM DENSpm for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210036Drug metabolism in human HepG2 cells assessed as SSAT2-mediated (N1-acetyl)-spermine formation at 1 mM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210035Drug metabolism in human HepG2 cells assessed as SSAT2-mediated (N1-acetyl)-spermidine formation at 1 mM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID496920Inhibition of human carbonic anhydrase 7 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210028Activity of human recombinant SSAT22013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210029Activity of human recombinant SSAT12013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID496915Inhibition of human carbonic anhydrase 3 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1210041Drug metabolism in human HepG2 cells assessed as SSAT2-mediated (N1-acetyl)-triethylenetetramine formation at 1 mM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID496921Inhibition of human carbonic anhydrase 9 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496924Inhibition of human carbonic anhydrase 14 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496922Inhibition of human carbonic anhydrase 12 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496913Inhibition of human carbonic anhydrase 1 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1131156Lipophilicity, log P of the compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antibacterial N-[omega, omega'-bis(alicyclic and aryl)-sec-alkyl]poly(methylene)triamine and -tetramine hydrochloride salts.
AID496925Inhibition of mouse carbonic anhydrase 15 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1210022Drug metabolism in human HepG2 cells assessed as SSAT-2-mediated (N1-acetyl)-triethylenetetramine formation at 1 mM TETA for 24 hrs in presence of SSAT1 shRNA2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID197832Binding constant for spermine binding to Ribonuclease S (RNA ase) by saturation curve method1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Design and semisynthesis of spermine-sensitive Ribonuclease S'.
AID83145Dose required to inhibit HLF cells by 50 percent2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Triethylene tetraamine: a novel telomerase inhibitor.
AID496916Inhibition of human carbonic anhydrase 4 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496917Inhibition of human carbonic anhydrase 5A by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496918Inhibition of human carbonic anhydrase 5B by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1210021Drug metabolism in human HepG2 cells at 1 mM for 24 hrs in presence of SSAT2 shRNA2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID496919Inhibition of human carbonic anhydrase 6 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (437)

TimeframeStudies, This Drug (%)All Drugs %
pre-199087 (19.91)18.7374
1990's72 (16.48)18.2507
2000's108 (24.71)29.6817
2010's117 (26.77)24.3611
2020's53 (12.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.87 (24.57)
Research Supply Index6.14 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index97.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (2.67%)5.53%
Reviews51 (11.33%)6.00%
Case Studies73 (16.22%)4.05%
Observational0 (0.00%)0.25%
Other314 (69.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies [NCT01178112]Phase 156 participants (Actual)Interventional2010-07-31Completed
Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus [NCT01295073]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to appropriate study medication supply could not be identified)
A Phase I, Single Centre, Randomised, Interventional, Open-Label, Cross-Over Study to Evaluate the Pharmacokinetics (PK) and the Safety and Tolerability of a Total Daily Dose of 900mg of TETA 4HCL, Comparing a New Once Daily TETA 4HCL Formulation (300mg) [NCT06128954]Phase 124 participants (Anticipated)Interventional2024-01-02Not yet recruiting
A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy [NCT04706429]Phase 2154 participants (Actual)Interventional2020-12-01Active, not recruiting
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy [NCT01213888]3 participants (Actual)Interventional2010-11-30Terminated(stopped due to Low enrollment & superior treatments available for diabetic macular edema including anti-VEFG therapies such as bevacizumab and ranibizumab.)
Phase I Trial of Copper Chelator in Conjunction With Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-resistant/-Refractory Epithelial Ovarian Cancer, Tubal Cancer and Primary Peritoneal Cancer [NCT03480750]Phase 1/Phase 218 participants (Actual)Interventional2012-09-30Completed
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients [NCT03299829]48 participants (Actual)Observational2018-01-10Completed
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma [NCT02068079]Phase 10 participants (Actual)Interventional2014-04-30Withdrawn
A Phase 1 Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson's Disease. [NCT01874028]Phase 120 participants (Actual)Interventional2013-05-31Completed
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease [NCT03539952]Phase 377 participants (Actual)Interventional2018-09-03Completed
Daily Vitamin D for Sickle-cell Respiratory Complications [NCT04170348]Phase 269 participants (Actual)Interventional2020-09-15Active, not recruiting
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease [NCT01472874]8 participants (Actual)Interventional2010-01-31Completed
Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [NCT02426905]Phase 490 participants (Anticipated)Interventional2016-01-31Active, not recruiting
[NCT00004339]Phase 390 participants Interventional1994-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01472874 (12) [back to overview]Albumin
NCT01472874 (12) [back to overview]Albumin
NCT01472874 (12) [back to overview]ALT
NCT01472874 (12) [back to overview]ALT
NCT01472874 (12) [back to overview]Cu Serum
NCT01472874 (12) [back to overview]Cu Serum
NCT01472874 (12) [back to overview]Cu Urine
NCT01472874 (12) [back to overview]Cu Urine
NCT01472874 (12) [back to overview]INR
NCT01472874 (12) [back to overview]INR
NCT01472874 (12) [back to overview]Zn Urine
NCT01472874 (12) [back to overview]Zn Urine
NCT03480750 (6) [back to overview]Maximum Plasma Concentration [Cmax] of Trientine
NCT03480750 (6) [back to overview]Maximum Tolerated Dose, MTD
NCT03480750 (6) [back to overview]Number of Participants With Dose-Limiting Toxicity (DLT)
NCT03480750 (6) [back to overview]Overall Survival
NCT03480750 (6) [back to overview]Progression-free Survival
NCT03480750 (6) [back to overview]Percentage of Participants With Measurable Tumor Treatment Response Assessed by RECIST Criteria 1.1
NCT03539952 (3) [back to overview]24-hour Urinary Copper Excretion (UCE)
NCT03539952 (3) [back to overview]Clinical Global Impression of Change (CGIC) Rating Scale
NCT03539952 (3) [back to overview]Serum NCC Concentration

Albumin

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Interventiong/dL (Mean)
Once a Day Trientine0.52

[back to top]

Albumin

(NCT01472874)
Timeframe: Pre Treatment (mean)

Interventiong/dL (Mean)
Once a Day Trientine0.54

[back to top]

ALT

Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

InterventionU/L (Mean)
Once a Day Trientine50.89

[back to top]

ALT

Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)

InterventionU/L (Mean)
Once a Day Trientine41.38

[back to top]

Cu Serum

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Interventionmcg/24h (Mean)
Once a Day Trientine0.52

[back to top]

Cu Serum

(NCT01472874)
Timeframe: Pre Treatment (mean)

Interventionmcg/24h (Mean)
Once a Day Trientine0.54

[back to top]

Cu Urine

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Interventionmcg/24hr (Mean)
Once a Day Trientine313.4

[back to top]

Cu Urine

(NCT01472874)
Timeframe: Pre Treatment (mean)

Interventionmcg/24hr (Mean)
Once a Day Trientine287.9

[back to top]

INR

The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Interventioninternational normalized ratio (Mean)
Once a Day Trientine1.05

[back to top]

INR

The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Pre Treatment (mean)

Interventioninternational normalized ratio (Mean)
Once a Day Trientine0.99

[back to top]

Zn Urine

(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)

Interventionmcg/24hr (Mean)
Once a Day Trientine2214

[back to top]

Zn Urine

(NCT01472874)
Timeframe: Pre Treatment (mean)

Interventionmcg/24hr (Mean)
Once a Day Trientine1959

[back to top]

Maximum Plasma Concentration [Cmax] of Trientine

Trientine (TETA) prior to and within 24 hrs and 7 days after trientine (NCT03480750)
Timeframe: 0, 10mins, 30mins, 60mins, 90mins, 120mins, 4h, 6h, 24h, 148h, 150h, 153h, 156h post 1st dose of trientine

Interventionmg/L (Median)
Trientine With Chemotherapy Dose Level 1 (300mg)1.87
Trientine With Chemotherapy Dose Level 2 (600mg)5.07
Trientine With Chemotherapy Dose Level 3 (900mg)11.54
Trientine With Chemotherapy Dose Level 4 (1200mg)14.98
Trientine With Chemotherapy Dose Level 5 (1500mg)13.08
Trientine With Chemotherapy Dose Level 6 (1800mg)29.35

[back to top]

Maximum Tolerated Dose, MTD

'3+3' study design. MTD will be defined at the dose level of trientine prior to the level with DLT events ≧ 2/6 participants. (NCT03480750)
Timeframe: within 36 days after the start of Trientine

Interventionmg (Number)
Trientine With Chemotherapy Dose Level 1 - 6 (300 -1800mg)NA

[back to top]

Number of Participants With Dose-Limiting Toxicity (DLT)

(1) Grade 4 neutropenia (ANC <500/cumm^3) or thrombocytopenia ≧7 days; (2) Hematologic toxicities ≧ Grade 3, eg. febrile neutropenia <1,000/cumm^3, or platelet count <25,000/cumm^3 with hemorrhage ≧ 7 days; (3) Non-hematologic toxicities ≧ grade 3, eg. ALT or AST, ≧ 7days; other non-hematologic toxicities ≧ grade 3 (except alopecia, non-chemotherapy related nausea/vomiting); (4) Neurologic toxicities ≧ grade 2, eg. dizziness, or lethargy ≧ 3 days (NCT03480750)
Timeframe: 36 days

InterventionParticipants (Count of Participants)
Trientine With Chemotherapy at Dose Level 1 (300mg/d)0
Trientine With Chemotherapy at Dose Level 2 (600mg/d)0
Trientine With Chemotherapy at Dose Level 3 (900mg/d)0
Trientine With Chemotherapy at Dose Level 4 (1200mg/d)0
Trientine With Chemotherapy Dose Level 5 (1500mg/d)0
Trientine With Chemotherapy Dose Level 6 (1800mg/d)0

[back to top]

Overall Survival

Time is calculated from the diagnosis to the date of the last follow-up date if no death event, or the date of death. (NCT03480750)
Timeframe: 36 months

Interventionmonths (Median)
Trientine With Chemotherapy14.4

[back to top]

Progression-free Survival

Time is calculated from the diagnosis to the last follow-up date if no disease progression , or the date of disease progression after the last treatment cycle of the study drugs (NCT03480750)
Timeframe: 36 months

Interventionmonths (Median)
Trientine With Chemotherapy4.6

[back to top]

Percentage of Participants With Measurable Tumor Treatment Response Assessed by RECIST Criteria 1.1

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan (NCT03480750)
Timeframe: 176 days

Interventionpercentage of participants (Number)
Clinical benefit ratesResponse rates
Trientine With Chemotherapy43.825.0

[back to top]

24-hour Urinary Copper Excretion (UCE)

24-hour urinary copper excretion (μg/ 24 hr) from urine collected by the patient over a 24-hour period. (NCT03539952)
Timeframe: Week 36

Interventionμg/24 hours (Mean)
TETA 4HCL274.5
Penicillamine510.8

[back to top]

Clinical Global Impression of Change (CGIC) Rating Scale

"The clinician will rate the change in the patient's Wilson's disease relative to the prior study clinic visit using a 7-point scale to a specific statement: 'Please rate the change in the overall severity of the patients Wilson's disease compared to the previous study clinic visit.~Available options were (1) very much improved; (2) much improved; (3) minimally improved; (4) no change; (5) minimally worse; (6), much worse; or (7) very much worse." (NCT03539952)
Timeframe: Week 36

Interventionscore on a scale (Mean)
Penicillamine4.1
TETA 4HCL3.9

[back to top]

Serum NCC Concentration

The primary outcome of efficacy was serum NCC by speciation assay (μg/L), with comparative analysis of mean difference between the two groups 24 weeks after randomization. The non-inferiority margin was set at -50 μg/L. (NCT03539952)
Timeframe: Week 36

Interventionµg/L (Mean)
Penicillamine Arm46.5
TETA 4HCL Arm58.7

[back to top]